CLINICAL_TRIALS
trial_result
· 2021-08-10
Clinical Trial Update: A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML [Phase 2]
Summary
Phase II study evaluating pembrolizumab as post-remission treatment in adults aged ≥60 with acute myeloid leukemia has completed accrual and results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Michael Boyiadzis | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-08-10